TPM Regimen (Thalidomide Prednisone and Methotrexate) in LGLL

  • STATUS
    Recruiting
  • End date
    May 20, 2025
  • participants needed
    42
  • sponsor
    Institute of Hematology & Blood Diseases Hospital
Updated on 19 February 2024
methotrexate
prednisone
lymphoid leukemia
leukemia
cytopenia
lymphoproliferative disorder
hepatosplenomegaly
large granular lymphocytic leukemia
t-cell large granular lymphocytic leukemia
clpd-nk

Summary

Large granular lymphocytic leukemia (LGLL) is a lymphoproliferative disease, with LGL infiltration in peripheral blood and bone marrow, hepatosplenomegaly, and cytopenia. Both T-LGLL and CLPD-NK are indolent disease and share similar biology and clinical course, and treated under the same strategy. So the investigators put them together as LGLL. The investigators used TPM regimen (thalidomide + prednison + methotrexate ) to treat LGLL since 2013, and 18/20 patients (90%) obtained clinical response, including 80% complete response. Adverse events (AE) of grade 3 and above are rare and safe. Therefore, the investigators designed this multicenter clinical trial to validate the efficacy of the TPM regimen in symptomatic T-LGLL and CLPD-NK.

Description

Because LGLL has continuously activated cytotoxic T lymphocytes, immunosuppressive therapy is the standard first-line therapy for T-LGLL and CLPD-NK. Previous studies showed that the overall response rate (ORR) of first-line oral immunosuppressants ranged from 21% to 85% (median: 50%). Both methotrexate and cyclosporine A are LGLL first-line treatment options, but the CR rate of methotrexate is only 21%, while the CR rate of CsA is less than 5%. There is insufficient evidence for the treatment of LGLL with prednisone and other glucocorticoids, but it can reduce RA-related inflammation and increase granulocyte levels. The TPM regimen was designed by the investigators. A pilot prospect observation showed that 18/20 (90%) patients obtained response, including 80% CR. This study is a prospective multiple center clinical trail to evaluate the efficacy of TPM regimen in the treatment of symptomatic LGLL. Eligible patients choose the initial treatment plan: thalidomide 50-100mg qn+ prednisone 0.5-1mg / kg qod +methotrexate 10mg / m2 / week. Four months is one course. Maximum three courses will be given if there is a response and thalidomide maintenance will be for another year.

Details
Condition T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA, Clpd-Nk
Age 18years - 100years
Treatment thalidomide + prednisone + methotrexate
Clinical Study IdentifierNCT04453345
SponsorInstitute of Hematology & Blood Diseases Hospital
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

The gender of the patient is not limited, and the age is 18 years old
Must meet diagnostic criteria of T-LGLL or CLPD-NK according to WHO 2016 version
The patient is treatment naive or received single methotrexate less than 4 weeks and without response. If relapsed or refractory patients, the patients must be naive for both thalidomide and methotrexate
With LGLL treatment indications, it mainly includes (meets at least one of the following conditions)
ANC <0.5 10^9 / L
HGB <100g / L or need red blood cell infusion to maintain
PLT <50 10^9 / L
Combining autoimmune diseases that require treatment
symptomatic splenomegaly
Severe B symptoms
Pulmonary hypertension
ECOG performance status score is 0-2
The patient's expected survival time is 6 months

Exclusion Criteria

Unable to understand or follow the research procedure
Co-occurrent malignant tumors that has to be treated or course the symptom
Other serious diseases, such as liver, kidney, heart, lung, nerve or metabolic diseases, may impede the ability of patients to tolerate methotrexate, cyclophosphamide or cyclosporin A
ALAT / ASAT or alkaline phosphatase> 3 times the normal value
Creatinine clearance <60ml / min
Serological evidence of active infection of HIV, hepatitis C or hepatitis B
Ineffective contraception
Positive pregnancy test
Pregnant women
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.